{"id":"mvc-cov1901-3-months","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fever"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant spike protein (S-2P) produced in mammalian cells, formulated with an aluminum adjuvant to enhance immunogenicity. It is administered as a 3-month regimen (typically 2 doses) to induce both humoral and cellular immune responses against the coronavirus spike protein, conferring protection against COVID-19 disease.","oneSentence":"MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:56:19.771Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 in adults"}]},"trialDetails":[{"nctId":"NCT05097053","phase":"PHASE4","title":"A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19","status":"UNKNOWN","sponsor":"Taoyuan General Hospital","startDate":"2021-10-07","conditions":"COVID-19 Vaccine","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"MVC-COV1901(3 Months)","genericName":"MVC-COV1901(3 Months)","companyName":"Taoyuan General Hospital","companyId":"taoyuan-general-hospital","modality":"Biologic","firstApprovalDate":"","aiSummary":"MVC-COV1901 is a recombinant protein subunit vaccine that stimulates immune responses against SARS-CoV-2 spike protein to prevent COVID-19 infection. Used for COVID-19 prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}